Curetis N.V. (Euronext: CURE), an Amsterdam, the Netherlands, and Holzgerlingen, Germany-based developer of next-level molecular diagnostic solutions, secured up to €20m in growth capital.
The capital was secured through the issuance of convertible notes by Curetis N.V. with share subscription warrants, to YA II PN, Ltd, an investment fund managed by Yorkville Advisors Global LP, a U.S.-based management firm (the “Investor” or “Yorkville”).
As of today, the company has drawn down €3.5m of the first tranche by issuing convertible notes and will thereby raise a net amount of €3.22m.
Curetis intends to draw down the remainder of the first tranche (i.e. €1.5m) within 90 trading days, subject to certain conditions being met.
The funding enables further acceleration of commercial expansion and R&D programs.
Led by Oliver Schacht, CEO, Curetis aims to bcome a leading provider of innovative solutions for molecular microbiology diagnostics designed to address the global challenge of detecting severe infectious diseases and identifying antibiotic resistances in hospitalized patients.
Its Unyvero System is an automated molecular diagnostic platform for cartridge-based solutions for the comprehensive and rapid detection of pathogens and antimicrobial resistance markers in a range of severe infectious disease indications. Results are available within hours, a process that can take days or even weeks if performed with standard diagnostic procedures. Unyvero in vitro diagnostic (IVD) products are marketed in Europe, the Middle East, Asia and the U.S.
Its wholly owned subsidiary Ares Genetics is developing next-generation solutions for infectious disease diagnostics and therapeutics.